Veeda Clinical Research Limited Unlisted Share Price
As of , the indicative unlisted share price of Veeda Clinical Research Limited is ₹428 per share. This is an over-the-counter reference price, not a stock-exchange quote.
As of , Veeda Clinical Research Limited is not listed on any Indian stock exchange (NSE or BSE) — its shares trade in the unlisted, over-the-counter (pre-IPO) market.
| Price / unit | ₹428 |
|---|---|
| Market cap | ₹2,815 Cr |
| Min. investment | ₹10,700 |
| Lot size | 25 |
| P/B ratio | 3.26 |
| ROE | -7.77% |
What is Veeda Clinical Research Limited?
Veeda Clinical Research Limited is an unlisted Healthcare company whose shares trade in India's over-the-counter (pre-IPO) market and settle in demat form (NSDL/CDSL).
Veeda Clinical Research Limited is an India-based contract research organisation (CRO) incorporated in 2004 and headquartered in Ahmedabad, Gujarat. The company provides end-to-end clinical research services to the pharmaceutical and biotechnology industry, spanning bioavailability and bioequivalence (BA/BE) studies, pre-clinical testing, early and late-phase clinical trials, bioanalytical work, pharmacovigilance, and medical writing. Veeda operates research facilities across Ahmedabad, Mehsana, and Bangalore, and has expanded through acquisitions including a stake in Bioneeds and the European CRO Heads, alongside a biosimilars joint venture. According to publicly available information, it has served clients across multiple countries and reports completing global regulatory inspections by authorities such as the USFDA. The company has filed a draft red herring prospectus (DRHP) with SEBI as part of a proposed public listing. As an unlisted, pre-IPO security, its shares carry higher risk, limited price transparency, and significantly lower liquidity than listed equities, and valuations can change sharply. This page is for information only and is not investment advice.
Explore more unlisted shares
Other companies in our curated selection.
Frequently asked questions
No. As of 16 July 2026, Veeda Clinical Research Limited is an unlisted company whose shares trade over-the-counter; it would list only if and when it completes an IPO.
The minimum lot is 25 share(s); at the indicative price of about ₹428, that is approximately ₹10,700. Indicative reference, not a quote.
As of 16 July 2026, the indicative unlisted share price of Veeda Clinical Research Limited is ₹428 per share. This is an over-the-counter reference price, not a stock-exchange quote.
The ISIN of Veeda Clinical Research Limited is INE01HQ01026. An ISIN is the unique 12-character code that identifies a company's shares in the depository system; this one is verified against NSDL (the National Numbering Agency). You need it to hold or transfer these unlisted shares in your NSDL or CDSL demat account.
Veeda Clinical Research Limited is an India-based contract research organisation (CRO) incorporated in 2004 and headquartered in Ahmedabad. It provides clinical research services to pharmaceutical and biotech companies, including bioavailability and bioequivalence (BA/BE) studies, pre-clinical and clinical trials, bioanalytical services, pharmacovigilance, and medical writing.
No. Veeda Clinical Research Limited is currently an unlisted company, and its shares trade in the private, unlisted market. The company has filed a draft red herring prospectus (DRHP) with SEBI for a proposed IPO, but the listing has not yet taken place. Whether or when an IPO proceeds is not certain.
Unlisted shares are transacted privately and credited to your demat account rather than through an exchange order book. To understand the current process and availability, you can contact the Unlisted Axis team for assistance. This is general information only and not investment advice; please make your own assessment.
Unlisted and pre-IPO shares carry higher risk and lower liquidity than listed shares. Prices are indicative and can change sharply, there is no certainty that an IPO will occur or proceed on any particular timeline, exit options may be limited, and the company's financial performance can fluctuate. Conduct your own due diligence before making any decision.
They can. If the company declares a dividend, unlisted shareholders are eligible like any other shareholder. Many unlisted firms reinvest profits, so dividends are not guaranteed.
After listing, unlisted shares convert into regular listed shares in your demat account and can be traded on the exchange, usually once any applicable SEBI lock-in period ends.
Unlisted shares are less liquid than listed shares. You can sell when a buyer is available through an off-market transfer; there is no continuous exchange market, so exits can take longer.
Unlisted shares carry higher risk and lower liquidity than listed shares, with fewer disclosures and no live market price. This is general information, not investment advice — assess suitability before investing.
An unlisted share price is an indicative, over-the-counter reference set by demand and supply in private deals between buyers and sellers. There is no live exchange quote, so prices can vary across dealers and over time.
Yes. Unlisted shares are delivered in dematerialised form, so you need an active demat account (NSDL or CDSL). No special account type is required — a regular demat account works.
Unlisted shares are sold through an off-market transfer to a buyer via a registered intermediary, settling from your demat account with a contract note. Liquidity depends on buyer availability, so exits can take longer than listed shares.
Veeda Clinical Research Limited vs similar unlisted Healthcare shares
Indicative over-the-counter prices, as of 16 July 2026. Information only — not a recommendation or ranking.